<DOC>
	<DOCNO>NCT00353327</DOCNO>
	<brief_summary>To study effect passive immunotherapy ( PIT ) HIV-viral load CD4 T+-cell count patient fail respond three different Highly-Active Antiretroviral Therapy ( HAART ) , moment less 100 CD4+-T cells/ml viral load 20,000 copies/ml .</brief_summary>
	<brief_title>Study Effectiveness Passive Immunotherapy HIV-Infected Patients Who Are Virologic Failure</brief_title>
	<detailed_description>Double blind comparative randomize study placebo two phase : Phase I : I : A pilot study asses virologic efficacy 30 patient do . They HAART regimen , randomize receive : 1 . Group I : HAART + PIT ( n= 15 ) 2 . Group II : HAART + placebo ( non-hyperimmune plasma ) ( n= 15 ) Passive immunotherapy consist 500 cc inactivate plasma methylene-blue ( standard inactivation method ) asymptomatic patient early phase infection . A transfusion do , complete blood test include viral load CD4+-T cell count do day 3 , 7 , 14 , 21 28 . The non-hyperimmune plasma ( Group II ) inactivate method . A second dose hyperimmune plasma placebo ( Group I Group II respectively ) administer +1 month begin trial . A complete blood test include viral load CD4+-T cell count do month +2 , +3 +4 . Phase II : 30 patient HAART regimen randomize receive : 1 . Group I : HAART + PIT ( n= 15 ) 2 . Group II : HAART + placebo ( non-hyperimmune plasma ) ( n= 15 ) Passive immunotherapy consist 500 cc inactivate plasma methylene-blue ( standard inactivation method ) asymptomatic patient early phase infection , guide neutralization capacity plasma donor virus ' receptor . A transfusion do , complete blood test include viral load CD4+-T cell count do day 3 , 7 , 14 , 21 28 . The non-hyperimmune plasma ( Group II ) inactivate method . A second dose hyperimmune plasma placebo ( Group I Group II respectively ) administer +1 month begin phase II . The patient remain HAART next year . A complete clinical examination , blood test include hemogram biochemical parameter ( renal hepatic function ) , viral load do month . Every three month , CD4+/CD8+ T cell count do , obtain plasma serum patient . Additionally , genotype virtual phenotype HIV obtain begin end study . Study end-points : -Main end-point : Phase I : proportion patient reduce plasma viral load &gt; = 1 log two infusion hyperimmune plasma . Phase II : proportion patient reduce plasma viral load &gt; = 1 log year . - Secondary end-points : 1 . Proportion patient whose CD4+ T cell count 100 cells/mm3 year . 2 . Proportion patient whose p24-antigenemia limit detection . 3 . Number mutation confer resistance antiretrovirals end study compare mutation begin . 4 . Type C event . 5 . Death . 6 . Toxicity . 7 . Adherence .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV1 infect patient ( CDC C category ) confirm Westernblot CD4 T cell count 100/ml form 6 month inclusion , never 600 CD4 T cells/ml last 6 month , even receive HAART . The patient receive least 3 different HAART regimen , fail respond ( define failure : CD4 T cell count 100/ml plasma viral load 20,000 copies/ml ) . Plasma viral load 20,000 copies/ml least 6 month . Written inform consent 18 year old old Asymptomatic patient fill A category CDC ( 1993 ) Younger 18 year old Who expect accomplish treatment follow visit Pregnancy , breastfeed woman , woman want get pregnant Denied consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>HIV</keyword>
	<keyword>Passive immunotherapy</keyword>
</DOC>